AU2012249646B2 - Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use - Google Patents

Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use Download PDF

Info

Publication number
AU2012249646B2
AU2012249646B2 AU2012249646A AU2012249646A AU2012249646B2 AU 2012249646 B2 AU2012249646 B2 AU 2012249646B2 AU 2012249646 A AU2012249646 A AU 2012249646A AU 2012249646 A AU2012249646 A AU 2012249646A AU 2012249646 B2 AU2012249646 B2 AU 2012249646B2
Authority
AU
Australia
Prior art keywords
cancer
leukemia
inhibitor
autophagy
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012249646A
Other languages
English (en)
Other versions
AU2012249646A1 (en
Inventor
Ravi K. Amaravadi
Jeffrey Winkler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
Original Assignee
University of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania filed Critical University of Pennsylvania
Publication of AU2012249646A1 publication Critical patent/AU2012249646A1/en
Application granted granted Critical
Publication of AU2012249646B2 publication Critical patent/AU2012249646B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012249646A 2011-04-29 2012-04-26 Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use Ceased AU2012249646B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161480641P 2011-04-29 2011-04-29
US61/480,641 2011-04-29
PCT/US2012/035251 WO2012149186A2 (en) 2011-04-29 2012-04-26 Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use

Publications (2)

Publication Number Publication Date
AU2012249646A1 AU2012249646A1 (en) 2014-02-27
AU2012249646B2 true AU2012249646B2 (en) 2017-06-08

Family

ID=47073068

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012249646A Ceased AU2012249646B2 (en) 2011-04-29 2012-04-26 Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use

Country Status (7)

Country Link
US (4) US20140050696A1 (enExample)
EP (1) EP2702054B1 (enExample)
JP (1) JP6162687B2 (enExample)
CN (1) CN103687853B (enExample)
AU (1) AU2012249646B2 (enExample)
CA (1) CA2841452C (enExample)
WO (1) WO2012149186A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140050696A1 (en) 2011-04-29 2014-02-20 Ravi K. Amaravadi Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
BR122021012629B1 (pt) 2013-02-01 2022-06-07 Wellstat Therapeutics Corporation Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos
WO2014147531A2 (en) * 2013-03-19 2014-09-25 Mahesh Kandula Compositions and methods for the treatment of cancer
JPWO2015133280A1 (ja) * 2014-03-03 2017-04-06 公立大学法人名古屋市立大学 抗マラリア活性化合物及び抗マラリア薬
EP3148547B1 (en) * 2014-06-02 2024-01-03 National Yang-Ming University Method for treating drug resistant cancer
US9926326B2 (en) 2014-07-14 2018-03-27 The Cleveland Clinic Foundation Substituted thioxanthenone autophagy inhibitors
EP3177595B1 (en) 2014-08-08 2021-02-24 The Trustees Of The University Of Pennsylvania Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
WO2016111957A1 (en) * 2015-01-06 2016-07-14 Albert Einstein College Of Medicine, Inc. Chloroquinoline triazole compounds, composition and uses
US10774047B2 (en) 2015-04-17 2020-09-15 The Trustees Of The University Of Pennsylvania Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy
WO2016175264A1 (ja) * 2015-04-28 2016-11-03 カルナバイオサイエンス株式会社 抗マラリア活性を有する新規ヘテロアリール誘導体
WO2016196393A2 (en) * 2015-05-29 2016-12-08 Presage Biosciences, Inc. Autophagy-inhibiting compounds and uses thereof
CN107007606B (zh) * 2016-02-04 2021-10-26 南京舒鹏生物科技有限公司 一种用于干燥综合症预防及治疗的药物及其组合
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2020243037A1 (en) * 2019-05-24 2020-12-03 The Trustees Of The University Of Pennsylvania Bisaminoquinolines and bisaminoacridines compounds and methods of their use
JP7652434B2 (ja) * 2019-09-18 2025-03-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がん治療のためのビアミノキノリンとナノ製剤
CN110559449B (zh) * 2019-10-22 2022-09-02 长治医学院 一种聚棉酚前药胶束及其制备方法
WO2021142065A1 (en) 2020-01-10 2021-07-15 Reyoung Corporation Acridin-9-yl-amine, quinolin-9-yl-amine, 1 -amino-9h-thioxanthene-9-one and benzo[b][1,5]naphthyri din-10-yl-amine derivatives as autophagy inhibitors for treating cancer
BR112023011284A2 (pt) 2020-12-09 2024-02-06 Wellstat Therapeutics Corp Composto de imidazoquinolina com atividade anti-inflamatória, antifúngica, antiparasítica e antineoplásica
CN115252615B (zh) * 2022-09-14 2023-10-24 重庆医药高等专科学校 一种含有防己诺林-7-丙酸酯与parp-1抑制剂的药物组合物
CN118576596A (zh) * 2023-03-01 2024-09-03 中国科学院上海药物研究所 Lys01或其盐在制备Kir4.1钾离子通道抑制剂中的应用
CN120309536A (zh) * 2024-06-28 2025-07-15 中山大学 桥连双喹啉化合物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB999237A (en) * 1962-06-22 1965-07-21 Rhone Poulenc Sa Quinoline derivatives
WO1997048705A1 (en) * 1996-06-19 1997-12-24 University College London Potassium channel blockers
US5756517A (en) * 1996-10-25 1998-05-26 Bayer Aktiengesellschaft Use of bisquinoline compounds in the treatment of cerebral disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2816893A (en) * 1957-12-17 Improvements in or relating to
GB726568A (en) * 1952-03-12 1955-03-23 Rhone Poulenc Sa Improvements in or relating to quinoline derivatives
DE1169948B (de) * 1961-06-06 1964-05-14 Dr Hans Carl Stark Verfahren zur Herstellung von antibakteriell wirksamen N, N'-Alkylen-1, 1'-alkylen-bis-(4-aminochinolinium-halogeniden)
US5510356A (en) * 1991-10-03 1996-04-23 University Of Nebraska Board Of Regents Bisquinolines and processes for their production and use to treat malaria
FR2796021B1 (fr) 1999-07-05 2001-10-19 Peugeot Citroen Automobiles Sa Poutre de pare-chocs pour vehicules automobiles
WO2001000218A1 (en) * 1999-06-30 2001-01-04 Scott Cordray Nasal spray having dead sea salts
CA2521619A1 (en) 2003-04-11 2004-10-28 Taigen Biotechnology Aminoquinoline compounds
US7574340B2 (en) * 2003-09-08 2009-08-11 The United States Of America As Represented By The Secretary Of The Army Small molecules and a pharmacophore model for inhibition of botulinum toxin and methods of making and using thereof
US20080269259A1 (en) * 2005-01-19 2008-10-30 The Trustees Of The University Of Pennsylvania Regulation of Autophagy and Cell Survival
US7973027B2 (en) 2006-02-27 2011-07-05 Nagoya City University Compound with antimalarial activity and antimalarial drug containing the same as active ingredient
CN101224207A (zh) * 2007-10-12 2008-07-23 中国科学院上海有机化学研究所 具有诱导自吞噬治疗错误折叠蛋白聚集所致疾病的药物及其筛选方法
EP2547367A4 (en) * 2010-03-16 2016-02-24 Ge Healthcare Bio Sciences Ab SYSTEM FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS
US20140050696A1 (en) 2011-04-29 2014-02-20 Ravi K. Amaravadi Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
EP3177595B1 (en) 2014-08-08 2021-02-24 The Trustees Of The University Of Pennsylvania Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
US20160168699A1 (en) 2014-12-12 2016-06-16 Asm Ip Holding B.V. Method for depositing metal-containing film using particle-reduction step
US10774047B2 (en) 2015-04-17 2020-09-15 The Trustees Of The University Of Pennsylvania Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB999237A (en) * 1962-06-22 1965-07-21 Rhone Poulenc Sa Quinoline derivatives
WO1997048705A1 (en) * 1996-06-19 1997-12-24 University College London Potassium channel blockers
US5756517A (en) * 1996-10-25 1998-05-26 Bayer Aktiengesellschaft Use of bisquinoline compounds in the treatment of cerebral disorders

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BURNETT, J.C., ET AL., "Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity". Biochemical and Biophysical Research Communications, 2003, vol. 310, pages 84-93 *
ELSLAGER, E.F., ET AL., Journal of Heterocyclic Chemistry, 1968, vol. 5, pages 599-607 *
GALANAKIS, D., ET AL., Bis-quinolinium cyclophanes: toward a pharmacophore model for the blockade of apamin-sensitive SKCa channels in sympathetic neurons". Bioorganic & Medicinal Chemistry Letters, 2004, vol. 14, pages 4231-4235 *
GIRAULT, S., ET AL., "Antiplasmodial Activity and Cytotoxicity of Bis-, Tris-, and Tetraquinolines with Linear or Cyclic Amino Linkers". Journal of Medicinal Chemistry, 2001, vol. 44, page 1658-1665 *
KLINGENSTEIN, R., ET AL., "Similar Structure-Activity Relationships of Quinoline Derivatives for Antiprion and Antimalarial Effects". Journal of Medicinal Chemistry, 2006, vol. 49, pages 5300-5308 *
SINGH, A.K. Chemical and Pharmaceutical Bulletin, 1975, vol. 23, no. 8, pages 1869-1873 *
SINGH, S., ET AL., "Characterization of Simian Malarial Parasite (Plasmodium knowlesi)-induced Putrescine Transport in Rhesus Monkey Erythrocytes". The Journal of Biological Chemistry, 1997, vol. 272, no. 21, pages 13506-13511 *
SRIVASTAVA, S., ET AL., "Synthesis of Bisquinolines and their in vitro ability to produce methemoglobin in canine hemolysate". Bioorganic and Medicinal Chemistry Letters, 1999, vol. 9, pages 653-658 *

Also Published As

Publication number Publication date
EP2702054A2 (en) 2014-03-05
CA2841452A1 (en) 2012-11-01
WO2012149186A2 (en) 2012-11-01
CN103687853A (zh) 2014-03-26
CN103687853B (zh) 2017-12-08
US20160168099A1 (en) 2016-06-16
US11591298B2 (en) 2023-02-28
EP2702054A4 (en) 2014-11-05
WO2012149186A3 (en) 2013-01-03
CA2841452C (en) 2021-04-13
US20170166530A1 (en) 2017-06-15
JP2014513101A (ja) 2014-05-29
JP6162687B2 (ja) 2017-07-12
AU2012249646A1 (en) 2014-02-27
US20140050696A1 (en) 2014-02-20
EP2702054B1 (en) 2018-10-24
US20200071272A1 (en) 2020-03-05
WO2012149186A9 (en) 2013-02-21
US10047052B2 (en) 2018-08-14

Similar Documents

Publication Publication Date Title
US11591298B2 (en) Bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
US11639335B2 (en) Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
US20210070712A1 (en) Dimeric Quinacrine Derivatives As Autophagy Inhibitors For Cancer Therapy
US20230348419A1 (en) Biaminoquinolines and nanoformulations for cancer treatment
WO2021060453A1 (ja) 架橋型光学活性２級アミン誘導体
KR20220062363A (ko) 암 표적성 약물 전달체로서의 인지질 에테르 접합체
AU2015240775B2 (en) Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
US20190231793A1 (en) Use of harringtonines in the treatment of breast cancer, in particular triple-negative breast cancer
WO2011094260A2 (en) Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer
HK1190718A (en) Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
WO2020243037A1 (en) Bisaminoquinolines and bisaminoacridines compounds and methods of their use
WO2016111957A1 (en) Chloroquinoline triazole compounds, composition and uses
WO2025211692A1 (ko) 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트
EA053296B1 (ru) Конъюгаты простого эфира фосфолипида в качестве носителей лекарственного средства для нацеливания на рак
KR20060007368A (ko) Ｎ-(3-클로로-1ｈ-인돌-7-일)-4-설파모일벤젠설폰아미드를포함하는 약제 조성물 및 세포 증식 억제제

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 29 DEC 2013 .

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired